Skip to main content
BMC Nephrology logoLink to BMC Nephrology
. 2021 Feb 2;22:49. doi: 10.1186/s12882-021-02242-z

Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Anja Gäckler 1,, Ulf Schönermarck 2, Vladimir Dobronravov 3, Gaetano La Manna 4, Andrew Denker 5, Peng Liu 5, Maria Vinogradova 6, Sung-Soo Yoon 7, Manuel Praga 8
PMCID: PMC7856751  PMID: 33530925

Correction to: BMC Nephrol (2021) 22:5

https://doi.org/10.1186/s12882-020-02190-0

Following publication of the original article [1], authors informed us that the PLS file was to be included in the supplementary information.

The original article [1] has been corrected.

Reference

  • 1.Gäckler A, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021;22:5. doi: 10.1186/s12882-020-02190-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Nephrology are provided here courtesy of BMC

RESOURCES